Let's hear it from all you, "You're just mad because Regeneron didn't hire you for a hospital rep job" people that refused to listen to anyone try to tell you how predictable this failure would be with the way it was handled.
Interviews held by Managers with no real experience in Athero along with a Human Resource lackey that ended with a primary care role play and you expected to hire the best of the best? You got your arse kicked by Amgen and now you have closed the Hospital Division - the best of the best allegedly - and you lost your patent fight. You teamed with Sanofi for crying out loud.
Hiring ignorant people that act like the are the cream of the crop and treating people like sh** does not work in the long run. Regeneron is now living proof.
"Praluent is not selling as well as we or others had expected."
http://seekingalpha.com/news/316801...e-amgen-ruling?app=1&uprof=45&dr=1#email_link
Enjoy those stock options!
"Chardan Capital's Gbola Amusa has downgraded Regeneron Pharma (NASDAQ:REGN) to Sell following Amgen's Repatha patent victory against Regeneron and Sanofi. His target has been cut by $50 to $325."
Don't be too upset though Regeneron reps, there are plenty of other pharma companies that would love to hire role play champions.
Interviews held by Managers with no real experience in Athero along with a Human Resource lackey that ended with a primary care role play and you expected to hire the best of the best? You got your arse kicked by Amgen and now you have closed the Hospital Division - the best of the best allegedly - and you lost your patent fight. You teamed with Sanofi for crying out loud.
Hiring ignorant people that act like the are the cream of the crop and treating people like sh** does not work in the long run. Regeneron is now living proof.
"Praluent is not selling as well as we or others had expected."
http://seekingalpha.com/news/316801...e-amgen-ruling?app=1&uprof=45&dr=1#email_link
Enjoy those stock options!
"Chardan Capital's Gbola Amusa has downgraded Regeneron Pharma (NASDAQ:REGN) to Sell following Amgen's Repatha patent victory against Regeneron and Sanofi. His target has been cut by $50 to $325."
Don't be too upset though Regeneron reps, there are plenty of other pharma companies that would love to hire role play champions.